

Date: 25 July 2018

Re: Freedom of Information Request
Ref: 56- 2018

Thank you for your email dated the 19th July 2018, providing clarification for the above mentioned FOI request.

The information that you require is as follows:

- 1. Within your health trust how many patients are currently [within the past 6 months available] being treated for head and neck cancer (Squamous cell carcinoma)?**

103 patients received SACT between October 2017 and March 2018

NB – A patient could have more than 1 line of SACT in this period.

203 patients have received radiotherapy

NB – A patient could have received both SACT and radiotherapy

- 2. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?**

Please Note – We only record stage at presentation to CCC, therefore if a patient presented with early disease and then progressed with metastatic disease, these patients will not be captured.

- a. Locally advanced**

10 patients had stage III disease at presentation to CCC

- b. Recurrent metastatic**

49 patients had stage IV or recurrent disease at presentation to CCC

3. Of the locally advanced/ recurrent or metastatic head and neck cancer patients how many are currently [within the past 6 months available]

Please Note – We only record stage at presentation to CCC, therefore if a patient presented with early disease and then progressed with metastatic disease, these patients will not be captured.

Carboplatin (only or in combination with 5-FU)

9 patients had Carbo with/or without another SACT

Cisplatin (only or in combination with 5-FU)

25 patients had Cisplatin with/or without another SACT or with/or without radiotherapy

Cetuximab (Erbix) with/without chemotherapy

8 patients had Cetuximab with/or without another SACT

Cetuximab (Erbix) with radiotherapy

8 patients had Cetuximab with radiotherapy

Docetaxel (Taxotere) -only or in combination with 5-FU Fluorouracil (5FU) Radiotherapy only

3 patients had Docetaxel in combination with 5FU and Cisplatin

Other

11 patients had "Other" = 4 x Nivolumab, 3 x Paclitaxel, 2 x Nimorazole/Placebo, 1 x Ipilimumab/Placebo+Nivolumab, 1 x AMG319/Placebo

4. Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials? –

Head and Neck studies: 5 studies open with a total of 69 patients recruited

5. Within your health trust how many patients are currently [within the past 6 months available] being drug treated for metastatic colorectal cancer?

Please Note – We only record stage at presentation to CCC, therefore if a patient presented with early disease and then progressed with metastatic disease, these patients will not be captured.

154 patients who presented to CCC with metastatic colorectal cancer received SACT between October 2017 and March 2018

NB – A patient could have more than 1 line of SACT in this period

19 patients who presented with colorectal metastatic disease received radiotherapy between October 2017 and March 2018

Of those patients please split by their drug treatment;

Cetuximab (Erbix) with/without chemotherapy

38 patients had Cetuximab with/without SACT

Panitumumab (Vectibix) with/without chemotherapy

0 patients had Panitumumab (Vectibix) with/without SACT

Nivolumab (Opdivo) with/without chemotherapy

0 patients had Nivolumab (Vectibix) with/without SACT

Chemotherapy + other mAb

2 patients had Bevacizumab + Capecitabine

Chemotherapy alone

142 patients had SACT alone

6. Does your health trust participate in any ongoing clinical trials for the treatment of colorectal cancer patients, if so how many patients are currently taking part in clinical trials?

Colorectal studies: 4 open studies with a total of 38 patients recruited

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>